GOOIMEER 2-35, NARRDEN, P7
Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
Material Contracts
Provides Corporate Update and Reports Second Quarter Financial Results
Investor Presentation
News
Reg. FD, Other Events
Q2
Q1
FY 2023
Q3
Amended Annual and Transition Report of Foreign Private Issuers
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload